In this interview, discover how Charles River uses the power of microdialysis for drug development as
well as CNS therapeutics.
well as CNS therapeutics.
Q&A: FDA’s Peter Marks ready to encourage more accelerated approvals for rare diseases
FDA biologics center director Peter Marks said the agency plans to encourage sponsors to use the accelerated approval pathway, particularly for rare disease treatments, as
August 17, 2023